# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Second quarter 2024 net cash used in operating activities is expected to be in the range of $32 million to $38 million. The ...
Study met primary safety endpoint; administration was well tolerated, with no serious adverse events observed Early and clin...
https://www.marijuanamoment.net/fda-expert-committee-will-review-mdma-assisted-therapy-for-ptsd-next-month/The Food and Drug Ad...
This is the latest of several collaborations for Compass, intended to better understand a range of potential approaches to deli...
Cantor Fitzgerald analyst Charles Duncan reiterates Compass Pathways (NASDAQ:CMPS) with a Overweight.
Cantor Fitzgerald analyst Charles Duncan reiterates Compass Pathways (NASDAQ:CMPS) with a Overweight.